![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
June 10, 2020
This phase III trial is testing the antibody durvalumab added to standard chemoradiation followed by durvalumab for one year, compared to standard chemoradiation followed by one year of the antibody
June 10, 2020
This phase II study is exploring the potent FLT3 inhibitor gilteritinib
June 10, 2020
TMIST will provide data that is critical for relating the increased rate of detection of early breast cancers to the clinical outcomes of the screening population
May 29, 2020
May 29, 2020
The purpose of this trial is to better understand the coronavirus' effect on people with cancer
April 15, 2020
For patients who have a pathologic complete response (pCR) after 12 weeks of pre-operative THP (single agent taxane plus trastuzumab and pertuzumab), is it safe to omit additional therapy after surgery?
April 15, 2020
A single-arm phase II trial evaluating the effectiveness of treatment before surgery with encorafenib and binimetinib
April 15, 2020
A one-of-a-kind cancer care delivery research trial that offers young women with cancer an assessment of their goals for fertility and family planning to make the most of cancer treatment and preserve future reproductive health
February 28, 2020
This trial is evaluating maintenance nivolumab versus observation following intensity-modulated radiation therapy and cisplatin
January 13, 2020
Lower chemoradiation doses may effectively treat early stage anal cancer while improving quality of life
January 13, 2020
January 13, 2020
